Compare AGCO & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGCO | MIRM |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | 22000 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 7.2B |
| IPO Year | 1994 | 2019 |
| Metric | AGCO | MIRM |
|---|---|---|
| Price | $120.97 | $113.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $119.09 | ★ $119.85 |
| AVG Volume (30 Days) | 625.6K | ★ 734.0K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.05% | N/A |
| EPS Growth | ★ 271.35 | 74.59 |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $10,082,000,000.00 | $19,138,000.00 |
| Revenue This Year | $6.52 | $26.22 |
| Revenue Next Year | $5.56 | $22.04 |
| P/E Ratio | $154.30 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $99.21 | $50.25 |
| 52 Week High | $143.78 | $130.00 |
| Indicator | AGCO | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 61.55 | 45.58 |
| Support Level | $109.31 | $87.93 |
| Resistance Level | $121.00 | $114.99 |
| Average True Range (ATR) | 3.42 | 5.09 |
| MACD | 0.46 | -1.87 |
| Stochastic Oscillator | 98.37 | 13.88 |
Agco is a global manufacturer of agricultural equipment. Its main machine brands are Fendt, Massey Ferguson, and Valtra; its initiatives in precision agriculture have been organized under the PTx umbrella following a series of acquisitions. While a global business, Agco's sales skew heavily toward Europe/Middle East, representing 50%-60% of sales and even more of operating profits. The company is trying to increase its exposure to the larger North and South American markets. Its products are available through a global dealer network, which includes over 3,000 dealers and distribution locations and reaches into over 140 countries. Additionally, Agco offers retail and wholesale financing to customers through its partnership with Rabobank of the Netherlands, having exited their JV in 2026.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.